secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0000950170-23-010112
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Therapeutics initiates Phase 1 study for oral GLP-1/GIP agonist VK2735; data expected H2 2023
--------------------------------------------------------------------------------

- Phase 1 trial of oral VK2735 tablet, dual GLP-1/GIP receptor agonist, in healthy adults with BMI ≥30.
- Randomized, double-blind, placebo-controlled study evaluating daily oral doses for 28 days.
- Primary objective: safety and tolerability; exploratory measures include body weight and plasma glucose.
- Top-line data anticipated in the second half of 2023.
- Prior subcutaneous Phase 1 showed up to 7.8% mean weight loss; Phase 2 for subcutaneous formulation planned for mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000095017023010112/0000950170-23-010112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000095017023010112/vktx-20230328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-010112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer